In this episode, Banu Arun, MD; Allison Butts, PharmD, BCOP; and Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP, discuss the role of BRCA testing and adjuvant olaparib in early breast cancer, including their experiences and challenges with implementing recent data. This overview will include discussion of:
- Data supporting the use of adjuvant PARP inhibition in early breast cancer and impact on BRCA testing and clinical practice
- The multidisciplinary role in ensuring that BRCA testing is completed for eligible patients
- Barriers to implementing BRCA testing and adjuvant olaparib in clinical practice and methods to overcome them
- Administration of adjuvant olaparib with other available adjuvant systemic therapies
- Tolerability of single-agent PARP inhibitors
Presenters:
Banu Arun, MD
Professor, Breast Medical Oncology
Director, Clinical Cancer Genetics
University of Texas MD Anderson Cancer Center
Houston, Texas
Allison Butts, PharmD, BCOP
Pharmacist Manager, Oncology
Director, PGY2 Oncology Residency Program
UK HealthCare
Assistant Adjunct Professor
UK College of Pharmacy
Lexington, Kentucky
Marissa Marti-Smith, MSN, APRN, AGNP-C, AOCNP
Nurse Practitioner
Breast Oncology
Texas Oncology Baylor Sammons Cancer Center
Dallas, Texas
Content supported by educational grants from AstraZeneca and Merck Sharp & Dohme Corp.
Link to full program:
https://bit.ly/42VeUMM
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
